Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study

Figures & data

Table 1. Baseline characteristics and demographics.

Characteristic	N = 324
Male, n (%)	206 (63.6)
Age, years	50.18 ± 13.67
Duration of psoriasis, years	18.16 ± 10.53
PsA, n (%)	117 (36.1)
Duration of PsA, years	9.45 ± 8.1
Previous treatments, n (%)	324 (100.0)
Acitretin	113 (34.9)
Cyclosporine	220 (67.9)
Methotrexate	151 (46.6)
Phototherapy	123 (38.0)
Biologics	222 (68.5)
Adalimumab	121 (37.3)
Certolizumab pegol	12 (3.7)
Etanercept	118 (36.4)
Golimumab	33 (10.2)
Infliximab	26 (8.0)
Ustekinumab	80 (24.7)
Naïve to biologic drugs, n (%)	102 (31.5)
Comorbidities, n (%)	216 (66.7)
Anxiety-depression disorder	12 (3.7)
Arthrosis	7 (2.2)
Asthma	4 (1.2)
Benign prostatic hyperplasia	8 (2.5)
Chronic gastritis	5 (1.5)
Celiac disease	1 (0.3)
Congestive heart failure	4 (1.2)
Coronary artery disease	15 (4.6)
Depression	7 (2.2)
Diabetes	45 (13.9)
Dyslipidemia	48 (14.8)
GERD	4 (1.2)
Hepatitis B	6 (1.9)
Hepatitis C	4 (1.2)
Hypertension	104 (32.1)
Latent tuberculosis	10 (3.1)
Obesity	30 (9.2)
Thyroid disease	10 (3.1)
Ulcerative colitis	2 (0.6)
Uveitis	1 (0.3)

Values are presented as mean ± standard deviation unless stated otherwise.

GERD, gastroesophageal reflux disease; PsA, psoriatic arthritis.

Table 2. Mean PASI, BSA and DLQI scores at baseline and at week 4, 24, 48, 60, 72 and 84.

Assessment	Baseline	W4	W24	W48	W60	W72	W84
PASI	15.3 ± 6.3	6.8 ± 5.0*	2.4 ± 2.8*	1.6 ± 2.6*	1.0 ± 2.4*	0.4 ± 1.2*	0.5 ± 1.0*
BSA	21.4 ± 14.4	9.3 ± 8.9*	3.4 ± 4.3*	2.7 ± 4.5*	1.5 ± 2.7*	0.8 ± 1.7*	0.7 ± 1.9*
DLQI	11.7 ± 2.8	4.0 ± 3.6*	1.7 ± 2.5*	0.5 ± 1.0*	0.6 ± 2.3*	0.3 ± 0.8*	0.2 ± 0.5*

Values are presented as mean ± standard deviation. *p < 0.001 vs baseline (assessed by unpaired Student’s t-test). BSA, Body Surface Area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area Severity Index; W, week.

Figure 1. Mean percentage change from baseline in Psoriasis Area Severity Index (PASI) score.

Table 3. Mean PASI, BSA and DLQI scores at baseline and at week 4, 24, 48, 60, 72 and 84 in patients who were naïve to biologic therapies (n = 102) and those with prior exposure (n = 222).

Assessment	Baseline	W4	W24	W48	W60	W72	W84
PASI
Naïve pts	15.5 ± 7.2	6.1 ± 5.7	1.6 ± 2.0	1.0 ± 1.7	0.4 ± 1.6	0.4 ± 1.3	0.5 ± 0.8
Non-naïve pts	15.2 ± 6.0	7.2 ± 4.7	2.8 ± 3.1	1.9 ± 3.0	1.4 ± 2.9	0.5 ± 1.6	0.7 ± 1.9
P	0.83	0.62	<0.001	<0.05	0.10	0.62	0.55
BSA
Naïve pts	23.1 ± 16.1	9.5 ± 10.6	2.8 ± 4.5	1.6 ± 3.0	1.1 ± 2.0	1.5 ± 2.9	0.7 ± 1.4
Non-naïve pts	21.0 ± 13.9	9.4 ± 8.5	3.7 ± 4.8	2.9 ± 4.7	1.7 ± 3.0	1.4 ± 2.1	1.1 ± 2.1
P	0.28	0.95	0.13	0.16	0.46	0.06	0.22
DLQI
Naïve pts	12.2 ± 4.6	3.0 ± 2.8	1.0 ± 1.5	0.3 ± 0.5	0.4 ± 0.8	0.4 ± 0.5	0.2 ± 0.6
Non-naïve pts	11.6 ± 2.9	4.2 ± 3.8	1.9 ± 2.7	0.6 ± 1.2	0.8 ± 2.8	0.3 ± 1.1	0.3 ± 0.9
P	0.42	0.19	0.14	0.38	0.29	0.36	0.52

Values are presented as mean ± standard deviation. BSA, Body Surface Area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area Severity Index; pts, patients; W, week. p-values are assessed by unpaired Student’s t-test.

Table 4. Mean PASI scores at baseline and at week 4, 24, 48, 60, 72 and 84 in patients who were obese (n = 30) and non-obese (n = 294) at baseline.

Assessment	Baseline	W4	W24	W48	W60	W72	W84
PASI
Obese pts	17.6 ± 7.2	8.7 ± 5.6	4.1 ± 4.8	2.8 ± 3.1	2.8 ± 2.2	1.4 ± 1.3	1.6 ± 2.1
Non-obese pts	15 ± 6.2	6.6 ± 4.9	2.1 ± 2.3	1.2 ± 1.8	1.0 ± 2.4	0.4 ± 1.1	0.7 ± 1.7
P	<0.05	<0.05	<0.001	<0.01	<0.01	<0.05	<0.05

Values are presented as mean ± standard deviation. PASI, Psoriasis Area Severity Index; pts, patients; W, week.